MyMD Pharmaceuticals (MYMD) Competitors $0.12 +0.00 (+2.07%) As of 07/3/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesOptions ChainSEC FilingsTrendsBuy This Stock MYMD vs. ASLN, CWBR, EVFM, PTPI, ATXI, TRVN, OGEN, NMTR, SRNE, and PBLAShould you be buying MyMD Pharmaceuticals stock or one of its competitors? The main competitors of MyMD Pharmaceuticals include ASLAN Pharmaceuticals (ASLN), CohBar (CWBR), Evofem Biosciences (EVFM), Petros Pharmaceuticals (PTPI), Avenue Therapeutics (ATXI), Trevena (TRVN), Oragenics (OGEN), 9 Meters Biopharma (NMTR), Sorrento Therapeutics (SRNE), and Panbela Therapeutics (PBLA). These companies are all part of the "pharmaceutical products" industry. MyMD Pharmaceuticals vs. Its Competitors ASLAN Pharmaceuticals CohBar Evofem Biosciences Petros Pharmaceuticals Avenue Therapeutics Trevena Oragenics 9 Meters Biopharma Sorrento Therapeutics Panbela Therapeutics ASLAN Pharmaceuticals (NASDAQ:ASLN) and MyMD Pharmaceuticals (NASDAQ:MYMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations. Is ASLN or MYMD more profitable? MyMD Pharmaceuticals' return on equity of -179.05% beat ASLAN Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ASLAN PharmaceuticalsN/A -8,454.87% -121.60% MyMD Pharmaceuticals N/A -179.05%-108.14% Which has preferable earnings and valuation, ASLN or MYMD? MyMD Pharmaceuticals has lower revenue, but higher earnings than ASLAN Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92-0.03MyMD PharmaceuticalsN/AN/A-$4MN/AN/A Do institutionals & insiders believe in ASLN or MYMD? 58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. Comparatively, 9.6% of MyMD Pharmaceuticals shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by company insiders. Comparatively, 2.1% of MyMD Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility and risk, ASLN or MYMD? ASLAN Pharmaceuticals has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, MyMD Pharmaceuticals has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500. Does the media favor ASLN or MYMD? In the previous week, ASLAN Pharmaceuticals' average media sentiment score of 0.00 equaled MyMD Pharmaceuticals'average media sentiment score. Company Overall Sentiment ASLAN Pharmaceuticals Neutral MyMD Pharmaceuticals Neutral SummaryMyMD Pharmaceuticals beats ASLAN Pharmaceuticals on 4 of the 7 factors compared between the two stocks. Get MyMD Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MYMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MYMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYMD vs. The Competition Export to ExcelMetricMyMD PharmaceuticalsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$280K$17.11M$5.50B$9.01BDividend YieldN/AN/A5.38%4.04%P/E RatioN/AN/A27.6020.30Price / SalesN/A16.32369.09103.84Price / CashN/AN/A36.6357.47Price / Book0.020.028.055.68Net Income-$4M-$15.61M$3.18B$249.13M7 Day Performance-5.82%-5.76%2.82%3.30%1 Month Performance-30.88%3.81%3.70%5.20%1 Year Performance-93.43%-35.48%35.41%21.38% MyMD Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYMDMyMD PharmaceuticalsN/A$0.12+2.1%N/A-93.6%$280KN/A0.006Gap DownHigh Trading VolumeASLNASLAN PharmaceuticalsN/A$0.60flatN/AN/A$1.23M$12M-0.0330CWBRCohBarN/A$0.41flatN/AN/A$1.19MN/A0.0010EVFMEvofem Biosciences0.8651 of 5 stars$0.01+1.0%N/A+4.7%$1.19M$11.39M-0.02120Gap DownPTPIPetros Pharmaceuticals0.6756 of 5 stars$0.04+11.6%N/A-99.7%$1.14M$5.11M-0.0120Gap DownATXIAvenue Therapeutics2.6065 of 5 stars$0.34-2.9%N/A-90.0%$1.08MN/A0.024Trending NewsGap DownTRVNTrevena1.631 of 5 stars$1.10+4.8%$5.00+354.5%-81.9%$1.06M$443K-0.0240Gap DownOGENOragenics0.2275 of 5 stars$1.47-5.5%N/A-95.1%$1.05M$40K-0.215High Trading VolumeNMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A-0.0220SRNESorrento Therapeutics0.7347 of 5 stars$0.00-36.4%N/A-81.7%$772K$60.32M0.00800News CoveragePBLAPanbela Therapeutics0.0863 of 5 stars$0.16-17.1%N/A-55.8%$764KN/A0.006 Related Companies and Tools Related Companies ASLN Alternatives CWBR Alternatives EVFM Alternatives PTPI Alternatives ATXI Alternatives TRVN Alternatives OGEN Alternatives NMTR Alternatives SRNE Alternatives PBLA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MYMD) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MyMD Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MyMD Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
